Sarah Price to Humans
This is a "connection" page, showing publications Sarah Price has written about Humans.
Connection Strength
0.504
-
Price SN, Lee JW, Gareen IF, Kircher SM, Kumar SK, Mayer IA, Saba NF, Fenske TS, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Park ER, Wagner LI. Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials. J Pain Symptom Manage. 2025 Apr; 69(4):370-384.
Score: 0.049
-
Price SN, Houston TK, Sadasivam RS, Wentworth S, Chandler A, Strahley A, Kittel C, Balakrishnan K, Weaver KE, Dellinger R, Puccinelli-Ortega N, Kong J, Cutrona SL, Foley KL, Sohl SJ. A qualitative study of stakeholders' experiences with and acceptability of a technology-supported health coaching intervention (SHARE-S) delivered in coordination with cancer survivorship care. Cancer Med. 2024 Jul; 13(13):e7441.
Score: 0.048
-
Price S, Hamann HA, Halaby L, Trejo J, Rogers FC, Weihs K. Collaborative depression care sensitive to the needs of underserved patients with cancer: Feasibility, acceptability and outcomes. J Psychosoc Oncol. 2024; 42(1):90-112.
Score: 0.044
-
Price SN, Palmer AM, Fucito LM, Graboyes EM, Baker NL, Rojewski AM, Toll BA. Tobacco use and cancer-related symptom burden: Analysis of the US Population Assessment of Tobacco and Health Study. Cancer. 2023 Aug 01; 129(15):2385-2394.
Score: 0.044
-
Price SN, Neil JM, Flores M, Ponzani C, Muzikansky A, Ballini L, Ostroff JS, Park ER. Patient-Reported Receipt of Oncology Clinician-Delivered Brief Tobacco Treatment (5As) Six Months following Cancer Diagnosis. Oncology. 2023; 101(5):328-342.
Score: 0.044
-
Price SN, Shen M, Rigney M, Ostroff JS, Hamann HA. Identifying Barriers to Advocacy Among Patients With Lung Cancer: The Role of Stigma-Related Interpersonal Constraint. Oncol Nurs Forum. 2022 Oct 20; 49(6):553-563.
Score: 0.042
-
Price SN, Hamann HA, Halaby L, Trejo JI, Corella F, Weihs KL. Poor Subjective Sleep Quality Among Patients with Cancer and Comorbid Depression: An Opportunity to Inform Screening and Intervention. Behav Sleep Med. 2023; 21(1):45-60.
Score: 0.040
-
Price SN, Flores M, Hamann HA, Ruiz JM. Ethnic Differences in Survival Among Lung Cancer Patients: A Systematic Review. JNCI Cancer Spectr. 2021 Oct; 5(5).
Score: 0.039
-
Price SN, Studts JL, Hamann HA. Tobacco Use Assessment and Treatment in Cancer Patients: A Scoping Review of Oncology Care Clinician Adherence to Clinical Practice Guidelines in the U.S. Oncologist. 2019 Feb; 24(2):229-238.
Score: 0.032
-
Price S, Hitsman B, Veluz-Wilkins A, Blazekovic S, Brubaker TR, Leone F, Hole A, Wileyto EP, Langer C, Kalhan R, Patel J, Schnoll R. The use of varenicline to treat nicotine dependence among patients with cancer. Psychooncology. 2017 Oct; 26(10):1526-1534.
Score: 0.027
-
Hunting JC, Price SN, Faucheux AT, Olson E, Elko CA, Quattlebaum A, Ruiz J, Lycan TW. Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study. Immunotherapy. 2025 Jan; 17(1):19-24.
Score: 0.012
-
Arditte Hall KA, Price SN, Lucas AR, Park ER, Wagner LI, Mizrach HR, Werner MH, Juhel BC, Goldstein MR, Gorman MJ, Hall DL. An exploration into the relationship between insomnia and repetitive negative thinking among cancer survivors. J Psychosoc Oncol. 2025; 43(1):59-72.
Score: 0.012
-
Weaver KE, Dressler EV, Smith S, Nightingale CL, Klepin HD, Lee SC, Wells BJ, Hundley WG, DeMari JA, Price SN, Foraker RE. Cardiovascular health assessment in routine cancer follow-up in community settings: survivor risk awareness and perspectives. BMC Cancer. 2024 Jan 31; 24(1):158.
Score: 0.012
-
Hunting JC, Faucheux AT, Price SN, Elko CA, Quattlebaum A, Bloomer C, Olson E, Petty WJ, Lycan TW. Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors. Immunotherapy. 2024 Apr; 16(6):381-390.
Score: 0.012
-
Palmer AM, Price SN, Foster MG, Sanford BT, Fucito LM, Toll BA. Urgent Need for Novel Investigations of Treatments to Quit E-cigarettes: Findings from a Systematic Review. Cancer Prev Res (Phila). 2022 Sep 01; 15(9):569-580.
Score: 0.010
-
Kaplan DM, Hamann HA, Price SN, Williamson TJ, Ver Hoeve ES, McConnell MH, Duchschere JE, Garland LL, Ostroff JS. Developing an ACT-based intervention to address lung cancer stigma: Stakeholder recommendations and feasibility testing in two NCI-designated cancer centers. J Psychosoc Oncol. 2023; 41(1):59-75.
Score: 0.010
-
Ver Hoeve ES, Ali-Akbarian L, Price SN, Lothfi NM, Hamann HA. Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors. Support Care Cancer. 2021 Jan; 29(1):349-358.
Score: 0.009
-
Sharma P, Bryer JS, Price S, Noe MH, Rosenbach M. A prospective comparison of cutaneous sarcoidosis disease response to immunomodulatory and immunosuppressive therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1546-1548.
Score: 0.009
-
Noe MH, Gelfand JM, Bryer JS, Price SN, Judson MA, Rosenbach M. Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument. JAMA Dermatol. 2020 Jan 01; 156(1):98-99.
Score: 0.009